6. CGA in Primary Care Settings: Medication review

Good practice guide
Good practices guides focus on providing information on a clinical topic.
British Geriatrics Society
Date Published:
28 January 2019
Last updated: 
28 January 2019

Medication review is a core component of CGA. Older patients with multiple comorbidities can have indications for multiple medications, some of which may be based on sound, relevant evidence, but others may do more harm than good, particularly in combination. 

The evidence base for guideline-based prescribing may not be directly relevant to frail older people or those with significant comorbidity (as such people are unlikely to have been represented in trial participants). Further, even established medications may no longer be useful as diseases may have run their course, physiology may have changed, or the reason for their prescription may have been to treat another drug’s side effect (e.g. amlodipine given for a single raised blood pressure, causes ankle swelling which is treated with furosemide, which causes urinary frequency treated with tamsulosin, which causes dizziness treated with betahistine). 

Finally, many medicines are given for long-term risk reduction (e.g. hypertension, renal disease in diabetes, lipid lowering), which may be less relevant to patients with a limited lifespan, and their use may not reflect current priorities.

Judicious review of medications, their indications, side effects, benefits and interactions can cause significant and rapid improvements in a patient’s condition. This does not always involve stopping medication; indeed increasing doses to effective levels or treating patient priorities such as limiting pain may be highly beneficial, or checking whether the medication can actually be taken or not might be particularly useful (e.g. inhaler technique, ability to put in eye-drops, frequency of PRN use). Below is a schema for a general approach to medication review (it is thorough but depending on prescribing complexity can be completed in 5-10 minutes), plus some validated tools to add rigour to the process. 

a.  Primary care prescription

b.  Pharmacy dispensation history

c.  Prescribed medications from other providers (e.g. private healthcare, from abroad)

d.  Other medications taken (e.g. leftover tablets, medicines prescribed for others)

e.  Herbal supplements, vitamins etc

f.  Illicit drugs

a.  In general: 

  • “Are you good at remembering your pills?”
  • “Can you swallow them OK?”
  • “What are you most concerned about with your tablets?”

b.  For each medication:

  • “Do you take this?”
  • “How often?”
  • “What for?”
  • “Do you think it works?”
  • “Does it have any side effects?”

The STOPP list (see below for details) or equivalent is useful here, as well as the BNF or e-prescribing decision support to check for interactions. This will guide further questioning.

  • If on anti-anginals: “How often do you get angina?”
  • If there is a previous history of stroke: “You’re not taking a blood-thinner. Do you know why that is?”
  • If on painkillers: “This tablet is a painkiller. What type of pain do you use it for? Does it work?”
  • If possible issues identified eg on STOPP: “Do you suffer from constipation?”

Review each medication for appropriateness given the medical history. The MAI can be useful here, at least as a framework for evaluating the key issues related to each medication

List and prioritise medication-related issues and discuss changes with the patient

a.  Any high-risk prescribing should be changed urgently

b.  Patient priorities are very important to both guide the process and build trust

c.  Changes should generally be introduced progressively over time unless there is a significant, urgent problem

d.  New medications should also usually be introduced one-by-one (to avoid confusion if prescribing or de-prescribing causes new symptoms)

e.  Reduce old medications gradually if necessary to avoid rebound effects (physiological or psychological dependence) and introduce new medications gradually too – start low and go slow.

f.  Arrange to assess progress and, if necessary, make further changes in the future.

The NO TEARS tool was developed in primary care and is said to be possible within a 10 minute consultation. It may therefore be a helpful part of CGA.  

It comprises a set of questions about an individual as follows

  • Need and indication
  • Open questions
  • Tests and monitoring
  • Evidence and guidelines
  • Adverse events
  • Risk reduction or prevention
  • Simplification and switches.

The STOPP-START decision aid is designed to support medication review particularly in older people. It consists of a series of rules/suggestions related to high-yield problems in prescribing for older people, both in terms of reducing medication burden (STOPP) and adding in potentially beneficial therapy (START). Short forms are being developed but are not yet published.

The Medication Appropriateness Index (MAI) is a framework for assessment of medications for older people. The MAI can be applied progressively to each medication to decide, individually and in combination with other medicines, whether the cost:benefit decision to prescribe the medication in question is appropriate. This tool is straightforward but painstaking as time needed increases progressively for each additional medication.

Feedback on this resource?

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.